En­tra­da hit with clin­i­cal hold on Duchenne drug

When En­tra­da Ther­a­peu­tics un­veiled its shiny new al­liance with Ver­tex days ago sur­round­ing my­oton­ic dy­s­tro­phy Type I, CEO Di­pal Doshi took the op­por­tu­ni­ty to spot­light a sep­a­rate pro­gram in Duchenne mus­cu­lar dy­s­tro­phy — which he was hop­ing to put in­to the clin­ic in 2023.

But a clin­i­cal hold from the FDA now threat­ens to de­lay those plans.

En­tra­da dis­closed late Mon­day that it re­ceived a clin­i­cal hold no­tice re­gard­ing its pro­gram for EN­TR-601-44, bar­ring it from start­ing a sin­gle as­cend­ing dose study in healthy vol­un­teers. Shares $TR­DA plum­met­ed 32% to $13.50.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER